Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ADVR and ONLY ADVR -- Ignore unavailable to you. Want to Upgrade?

To: Bernie Bildman who wrote (70)	9/25/2000 9:05:52 PM
From: Bernie Bildman	Respond to of 278

More on the recent SEC filing:: "We are currently evaluating the costs and time necessary to proceed with Phase I clinical trials in Argentina." There have been reports lately that testing in Argentina is ongoing, however in this most recent filing it seems testing is NOT underway. Anyone have info regarding this?? Also, it's my opinion that the recent loss of interest (read that 'disappointment') on the message boards and the price levels we are moving toward can be explained: (1) to some extent by the anticipation of some kind of 'major' news following the poster presentations and the letdown of nothing developing (2) the anticipation of an IND filing/approval being announced, with no news whatsoever. I for one was one of those who thought we'd be looking at the IND by now. I was wrong and I feel it will be better to foregoe predictions of such for our own sanity. ceoa+ on RB stated it correctly...that it will be here when it gets here. However, I feel if nothing develops by year's end, there'll be a price to pay in the way of selling off by many investors who targeted end of year as a LAST possible point to move forward with IND news. Something dramatic by that point in time should develop, either IND submission/approval or postponement - with the announced 'end of year' time frame offered by the company. So, with a wish in my heart for good news for us all, I'm going to put off any expectations until end of year time and play it easy.

To: Bernie Bildman who wrote (70)	9/25/2000 10:08:53 PM
From: Kingfisher	Read Replies (2) \| Respond to of 278

Bernie, here are my thoughts on the following paragraphs from your post: 1. "(ii) an injunction against Advanced Viral from further attempts to use, market or assert any claims of ownership over any broad/exclusive rights in Reticulose, or the use, publication or disclosure of information regarding Reticulose;" As I noted in an earlier post this morning, the absence of the word "Reticulose" was very evident in Dr. Hirschman's interview of today. How may posts have we seen on a number of threads trying to convince us that Product R is something different from Reticulose. It would appear that if Product R is significantly different or better than Reticulose, the question as to who has the rights to Reticulose becomes a mute point, don't you think? 2. "does anyone know (or find out) if this suit is in any way delaying any of the ongoing drug application processes? Does this suit have to be settled BEFORE any IND can be filed?" In talking to ADVR south via phone the answer to these questions was that the law suit(s) will in no way delay the IND application. 3. Will this suit impact in any way the possibility of attracting investors, possible partners and other integral personnel to the company?? With regard to attracting investors — well the first day the litigation was made public in the SEC document the stock hit a lower low in its downward trend. IMO, this litigation, like any litigation, should not help in attracting investors until it is resolved. With regard to possible partners — that depends in how convincing Dr. Hirschman can be in selling a deal with a bomb under his chair. After all, he has been successful in selling some more shares.

To: Bernie Bildman who wrote (70)	9/25/2000 11:27:07 PM
From: DAN LITTLE	Read Replies (2) \| Respond to of 278

What I find myself asking about this lawsuit is. How could it have ever gotten this far? I mean, did Chuck Miller bring Reticulose to ADVR or did ADVR bring Reticulose to Chuck Miller? I don't know all the facts in this case, but it seems pretty clear cut on the surface. I am also not naive enough to think that it isn't legally possible to rip off a company and get away with it. ADVR believes it to be without merit. They are going ahead with Product R. They just secured the money to get them into Phase I testing. They have hired Globomax and many new scientists. They have added to and updated there Yonkers facility. Dr. Hirschman's contract has been extended for another two years. Certainly doesn't sound like a company that believes the lawsuit has a chance in hell. Sure wish we could answer all the lawsuit questions, but we can't. I sure wish someone out there would step forward and give us some answers. Dan